The Top 4 COVID-19 Vaccine Stocks to Watch


The world is desperate for a vaccine.

The good news is – we may be nearing one this year.

Pfizer (PFE) and BioNTech (BNTX)

Pfizer (PFE) CEO Albert Bourla just said there’s a “good chance” the company will know if its vaccine works by the end of October 2020.

The CEO told Face the Nation, “We started already manufacturing and we have already manufactured hundreds of thousands of doses, so just in case we have a good study readout, conclusive and FDA, plus the advisory committee feels comfortable that we will be ready.”

The company, along with BioNTech (BNTX) has already begun enrolling 30,000 people in its Phase 3 vaccine trial.  However, it’s now looking to expand that enrollment to 40,000, as it attempts to expand to far more vulnerable populations.

Eli Lilly (LLY)

Eli Lilly is seeing a reduction in the hospitalization rate with its vaccine.

“The U.S. drug maker said it tested three different doses of LY-CoV555 against a placebo in a trial enrolling roughly 450 patients. The middle dose of 2,800 mg met the trial’s target of significantly reducing the presence of SARS-CoV-2 after 11 days,” said CNBC.

Moderna (MRNA)

Moderna just said it’ll know by November 2020 if its vaccine works, says CEO Stephane Bancel.  If it is, the company could deliver 100 million doses to the U.S. government in the first few months of next year.

“Moderna’s experimental vaccine contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus. In July, the company released early-stage data that showed its potential vaccine generated a promising immune response in a small group of patients,” as reported by CNBC.


Please enter your comment!
Please enter your name here